By: Mandy Jackson
Ouro Medicines, founded by Monograph Capital and GSK and helmed by HI-Bio veterans, aims to reset the immune system in B-cell-mediated diseases with options that are not CAR-T therapies.
Not enough data
Mandy Jackson's coverage focuses on the healthcare and pharmaceutical industry, particularly on drug development, FDA approvals, and biopharmaceutical companies. Additionally, she covers financial aspects related to these sectors.
Given her focus on press releases and private sector announcements, Mandy would likely be responsive to pitches that provide exclusive insights into new drug developments or financial activities within the healthcare and pharmaceutical industries. She may also be interested in expert commentary regarding regulatory changes impacting drug development or financial trends affecting biopharmaceutical companies.
While no specific geographic focus is mentioned for Mandy's coverage area, it’s important to note that her articles cover global developments in the healthcare and pharmaceutical sectors as well as finance-related topics relevant to these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .